· 1994.9 - 1997.6

Saarland University Med. School, Homburg, Germany   - Medical Biochemistry   - 博士

· 1997.9 - 2000.6

Saarland University, Germany   - Biochemistry   - Postdoctoral

· 1987.9 - 1994.6

Saarland University, Germany   - Science Chemistry   - 硕士

· 2012.9 - 2014.6

 Department of Biochemistry, Saarland University, Germany → Lecturer & Senior Scientist 

· 2008.9 - 2012.6

 PomBioTech GmbH, Germany → CEO 

· 2004.9 - 2008.6

 Department of Biochemistry, Saarland University, Germany → Senior Scientist (C2) 

· 2001.9 - 2004.6

 Department of Biochemistry, Saarland University, Germany → Senior Scientist (C1) 

· A primary aim is to search for compounds that can act as CYP4Z1-activated prodrugs (right figure) and have potential for treatment of breast cancer.

·  In addition, additional substrates of this enzyme that are both structurally different and far better suited to screening procedures than fatty acids have been identified

· This is expected to aid doctors in choosing the correct dosage for patients. In the second area, the group has successfully identified CYP4Z1 to be a fatty acid in-chain hydroxylase.

· A primary goal in the first area involves systematic testing of all variants of drug metabolizing cytochrome P450 enzymes (CYPs or P450s; see left figure below) and UDP glycosyltransferases (UGTs) identified in Chinese patients.

· 2) investigation of human CYP4Z1 and the treatment of breast cancer.

·  1) Human drug metabolizing enzymes